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Proposals submitted to the FDA for MSC-based products are undergoing a rapid expansion that is charac-
terized by increased variability in donor and tissue sources, manufacturing processes, proposed functional
mechanisms, and characterization methods. Here we discuss the diversity in MSC-based clinical trial prod-
uct proposals and highlight potential challenges for clinical translation.Introduction
MSCs, commonly referred to as mesen-
chymal stem cells or mesenchymal stro-
mal cells, are a diverse population of cells
with a wide range of potential therapeutic
applications. Despite considerable inter-
est and effort, there are currently no
FDA-approvedBiologics LicenseApplica-
tions (BLAs) for anyMSC-basedproducts.
There is also no consistent nomenclature
or definition of MSCs (Keating, 2012). In
2006, the International Society for Cellular
Therapy (ISCT) proposed a set of minimal
criteria to characterize MSCs (such as
cell surface marker expression). More
recently, researchers in the MSC field
have shown that these commonly
described markers are not distinctive
and therefore may not be sufficient for
defining the cellular composition and bio-
logical function or functions of an MSC-
based product. Although not an FDA
requirement, stakeholder efforts toward
generating consensus on MSC definitions
would be a useful development for the
field, which would allow comparison
across multiple studies and could facili-
tate potential clinical use. In order to better
understand the composition, phenotype,
and range of bioactivity for MSCs, it may
be useful to be able to correlate MSC sur-
face and/or secreted protein markers with
their in vitro and in vivo bioactivity. How-
ever, incomplete knowledge about MSC
mechanisms-of-action (MOAs) and how
these may relate to outcomes for different
clinical indications and routes of adminis-
trationmake such comparisons especially
difficult. It is important to note that the FDAreviews each regulatory submission
based on its own merits, and nomencla-
ture is not a regulatory concern during
early clinical development. Closer to licen-
sure, however, nomenclature assumes
greater significance for regulatory require-
ments, such as product labeling.
In order to track emerging trends in this
rapidly expanding field, we assessed
initial filings of 66 Investigational New
Drug (IND) submissions to the FDA for
MSC-based products and MSC-related
information from worldwide clinical trial
registries (as of December, 2012). We
limited our assessment to MSC-based
products that were used in similar ways
to avoid potential confusion that would
arise from making less biologically rele-
vant comparisons. For example, we
excluded whole bone marrow mononu-
clear preparations even when the sponsor
described their product using MSC termi-
nology. We also excluded trials that only
used MSCs during manufacturing of a
final cell therapy product (e.g., MSCs
used for ex vivo culture only) in which
MSCs were not administered to patients.
Our analysis revealed a high degree of
variability in terms of MSC sources,
manufacturing processes, and in vitro
and in vivo product characterization.
This lack of consensus highlights poten-
tial challenges to the clinical translation
of MSC-based products.
Donor and Tissue Source Diversity
in MSC-Based Product INDs
There was an approximately 3-fold in-
crease in the number of MSC-basedCell Stem Cell 14product IND submissions to the FDA
between 2006 and 2012 in the set we
assessed. In this period, there was also
a substantial increase in registered MSC
clinical trials initiated worldwide (246 tri-
als; source: http://www.clinicaltrials.gov,
‘‘Mesenchymal Stem OR Mesenchymal
Stromal,’’ queried in January, 2013).
Despite this rapid expansion in clinical
trials and calls for revised nomenclature,
the original terminology (Mesenchymal
Stem Cell) still appears to predominate.
We found that the term ‘‘Mesenchymal
Stem Cell’’ was used to describe 72%
of MSC-based product registered clinical
trials worldwide, and 76% of MSC-based
products in original IND submissions
prior to 2013. As the number of
registered clinical trials worldwide and
MSC-based product IND submissions
increased, the diversity in donor and
tissue source increased as well. Donor
source diversity refers to whether the
cells were isolated from an autologous
(self) or allogeneic (non-self) donor. It
also refers to the variability observed
between donors, which could be related
to age and health of the donor among
other factors. Almost all MSC-based
product INDs prior to 2008 were sourced
from allogeneic donor bone marrow
(e.g., 100% in 2006). Since then, MSC
donor and tissue source diversity has
significantly increased. For example, the
percentage of allogeneic MSC-based
products being evaluated under IND
decreased to 42% in 2011 (the only
year the percentage dropped below
50% prior to 2013) and increased to, February 6, 2014 ª2014 Elsevier Inc. 141
Figure 1. The Tissue Source for MSC-Based Product INDs Has
Become Diverse over Time
Data from original IND submissions were compiled (n = 66). The percentage of
bone-marrow-derived MSC-based product INDs is displayed per year.
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product INDs in 2012.
One parameter that signifi-
cantly affects how MSCs are
described according to the
literature is tissue source
(Phinney and Sensebe´,
2013). Strikingly, the propor-
tion of the 66 IND submis-
sions that evaluated MSC-
based products derived from
bone marrow was 100%
through 2007 but decreased
to 55% by 2012 (Figure 1).
Prior to 2013, the second
most common source under
IND was umbilical cord or
placental tissue; the third
most common was adipose
tissue. The number of adi-pose-derived MSC-based product INDs
has increased significantly since 2011
(there was a 3-fold increase between
2011 and 2012 alone). This shift is consis-
tent with clinical trials registered world-
wide, where less than half of the MSC-
based product trials registered in 2012
used bone marrow as a source.
Manufacturing Diversity in
MSC-Based Product INDs
MSC researchers and manufacturers
use awide range of protocols tomanufac-
ture their MSC-based products. Of these
manufacturing differences, we assessed
four prominent parameters that have the
potential to influence product characteris-
tics: (1) fetal bovine serum (FBS), (2) atmo-
spheric oxygen (21%), (3) cryopreserva-
tion of the final product, and (4) cell
banking (working or master cell bank).
The majority of regulatory submissions
(over 80%) describe the use of FBS during
manufacturing. The range of FBS concen-
tration in media ranges from approxi-
mately 2%–20%, with 10% FBS the
most common concentration. Different
percentages of FBS result in different
amounts of growth factors present in a
culture, thus some MSC manufacturers
emphasize the importance of qualifying
FBS lots to facilitate product compara-
bility between manufacturing runs. How-
ever, it may be challenging to determine
which tests and product characteristics
(i.e., critical quality attributes) are the
most appropriate to select for compari-
son. The choice of assays and/or markers
tested can be just as challenging for142 Cell Stem Cell 14, February 6, 2014 ª201implementing manufacturing process
changes with respect to demonstrating
final product comparability (Carmen
et al., 2012). The most common alterna-
tive for FBS described in regulatory sub-
missions is human platelet lysate, where
performing qualification and demon-
strating comparability are similarly impor-
tant. Many submissions describe the
use of growth factors in addition to serum
(25%). Importantly, many sponsors
describe process development to include
replacing the use of animal-derived serum
during their manufacturing process.
Most (90%)MSC-based product sub-
missions describe the use of atmospheric
oxygen during cell culture. Some groups
have described the utility of more physio-
logical oxygen conditions for MSC manu-
facture (e.g. low oxygen tension, such as
5% O2).
The majority of MSC-based product
regulatory submissions (over 80%) also
describe the use of cryopreservation to
store and transport their final product,
which is usually thawedwithin a few hours
of patient infusion. Recently, MSC re-
searchers have described challenges
inherent in assessing the potential func-
tionality of MSCs after thawing immedi-
ately before infusion, especially when
bioactivity assays are often performed
onMSCs prior to or without cryopreserva-
tion, or following culture rescue (Gali-
peau, 2013). A common postthaw test
described in an MSC-based product
regulatory submission is viability, ex-
pected to exceed 70% for intravenously
administered MSCs. However, it is un-4 Elsevier Inc.clear how relevant viability is
for MSC functionality immedi-
ately postthaw especially
when considering the poten-
tial for delayed cytotoxicity
(e.g., 24–72 hr). For example,
there is no well-documented
evidence that MSCs have
the ability to produce and
secrete factors produced de
novo in response to microen-
vironmental cues immediately
postthaw.
A smaller proportion (35%)
of regulatory submissions
described the use of cell
banking systems. When cell
banking is employed, a multi-
tiered system (e.g., master
cell bank and working cellbank) is described about one-third of the
time. If a cell banking system is described,
we have found that MSCs, in general, are
grown to a higher range of passage
numbers or population doublings tomanu-
facture the final product. Even when no
banking system is employed, there is a
wide range of passages or population
doublings described to manufacture the
final product. For example, passage
numbers approaching ten have been
noted. Although population doubling data
is more informative, it is often not
described. Given the logistical require-
ments of a cell banking system, all banked




in MSC-Based Product INDs
We found substantial variability in the
panel of cell surface markers proposed
for characterization of MSC-based prod-
ucts in FDA regulatory submissions in
terms of frequencies and ranges of
expression (Table 1). The number of
MSC markers used for characterization
at different stages (i.e., in-process and/
or lot release testing) is also variable (Ta-
ble S1 available online). In general, even
in cases where many markers are stud-
ied ‘‘for information purposes only,’’
only a select few markers are proposed
for lot release criteria. Although there is
variability in the proposed marker criteria
described in a given MSC-based product
regulatory submission, seven of the nine
initial ISCT-proposed markers (Dominici
Table 1. MSC-Based Product Phenotypic Marker Expression Proposed in MSC-Based Product INDs
Usage RANK
Common Product




Described Av. Min. % ± SD Av. Max. % ± SD
1 CD45 91 2 58 0 ± 0 7 ± 6.84
2 CD105 73 1 67 88 ± 7.54 100 ± 0
3 CD90 61 3 36 87 ± 7.17 100 ± 0
4 CD73 52 4 29 86 ± 7.24 100 ± 0
5 CD34 48 7 21 0 ± 0 9 ± 6.56
6 CD14 47 6 24 0 ± 0 7 ± 7.00
7 HLA Class II 44 5 27 0 ± 0 9 ± 7.15
8 CD44 30 — — — —
9 HLA Class I 26 10 14 74 ± 18.60 100 ± 0
10 CD29 24 — — — —
11 CD106 23 — — — —
12 CD19 21 — — — —
13 CD80 21 — — — —
14 CD86 21 — — — —
15 CD166 20 8 18 92 ± 4.52 100 ± 0
16 CD10 18 — —
17 CD146 15 9 15 67 ± 4.83 100 ± 0
18 CD40 15 — — — —
19 CD11b 14 — — — —
20 CD200 12 — — — —
The top 20 product markers are displayed and ranked as aggregate data in terms of percent usage across all original MSC submissions analyzed (n =
66). ‘‘% Usage’’ refers to how often a particular marker is qualitatively proposed at any stage of product characterization across all MSC submissions
analyzed (i.e., positive or negative). In addition, the top 10 product markers, described using quantitative ranges of expression proposed, are displayed
and ranked as aggregate data in terms of percent usage across all originalMSC submissions analyzed (n = 66). ‘‘%with range described’’ refers to how
often a particular marker was proposed with a quantitative range of expression. ‘‘Av. Min. ± SD’’ refers to the average minimum value in the range of
expression, plus or minus the standard deviation. ‘‘Av. Max. ± SD’’ refers to the average maximum value in the range of expression, plus or minus the
standard deviation. Positive markers are in bold and negative markers are in italics. All percentages are rounded to the nearest whole percent value,
and standard deviations are to two decimal places.
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Forumet al., 2006) are ranked at the top of the
list (Table 1). The same top seven
markers were specifically utilized for lot
release criteria, such as for sponsor-pro-
posed identity and purity (see FDA’s
guidance document for more information




pdf). We found that most of the MSC-
based product IND submissions propose
some subset of seven of the initial ISCT-
proposed marker criteria (CD105, CD73,
CD90, CD45, CD34, CD14, and HLA
class II), albeit with more loosely defined
ranges of expression. For example,
instead of CD105 expression levels at
95% or greater as per ISCT-proposed
criteria, MSC-based submissions pro-
pose CD105 expression levels as low
as 80%. It is unclear whether the quan-
titative difference in expression levels
proposed is relevant in terms of overallMSC product characterization. The
same seven markers are arguably the
most commonly described in the litera-
ture as well (Mafi et al., 2011).
MSC-Based Product Bioactivity
Characterization In Vitro and In Vivo
We also found significant heterogeneity in
descriptions of MSC bioactivity charac-
terization in situations where a candidate
marker for a given assay has been
defined. ‘‘Candidate marker’’ refers to a
molecular marker that may be correlated
with bioactivity. Examples include a
secreted factor, or expression of proteins
on the surface of either theMSCs or target
cells (e.g., T cells) that may be related to a
given biological activity. Such candidate
markers are often proposed by the
sponsor as the potential basis for a po-
tency assay during clinical development
(an industry perspective on cell therapy
potency is reviewed in Bravery et al.,
2013); also, the FDA has published a guid-Cell Stem Cell 14ance document on cell therapy potency




UCM243392.pdf). Our survey found that
less than half of the initial MSC-based
product IND submissions describe
marker-based bioactivity assays. Of the
regulatory submissions that did contain
such descriptions, most were submitted
by commercial sponsors using MSCs
from allogeneic donors. The described
markers of bioactivity include factors
secreted from MSCs, such as proangio-
genic growth factors or anti-inflamma-
tory/Th2 cytokines, as well as markers
tested in MSC-leukocyte coculture prolif-
eration assays. Another consideration
that can be taken into account is emerging
evidence that MSC tissue source may
impact bioactivity. In one example, adi-
pose-derived MSCs were found to have a
greater immunosuppressive capacity on, February 6, 2014 ª2014 Elsevier Inc. 143
Cell Stem Cell
ForumT cells and monocytes via increased
expression/secretion of anti-inflammatory
factors in comparison to bone-marrow-
derived MSCs (Melief et al., 2013).
MSC bioactivity may also be depen-
dent on product-specific factors, clinical
indication, and route of administration.
Many groups have shown the influence
of the microenvironment on cell bioac-
tivity. Given the responsiveness of MSC
characteristics to microenvironmental
cues, we looked at target clinical indica-
tions for MSC-based product regulatory
submissions and proposed routes of
administration. We found that MSCs-
based products are being investigated
for a wide range of clinical indications.
Cardiovascular and neurological targets
are the most common, with orthopedic
targets not far behind (out of the same
66 MSC-based product INDs prior to
2013). In addition, nearly one-fourth of
MSC-based product regulatory submis-
sions propose to investigate indications
characterized primarily by immune-medi-
ated disease attributes, such as for treat-
ment of Graft versus Host Disease
(GvHD). Multiple routes of administration
are proposed. Just over half of submis-
sions surveyed propose intravenous,
while the other half proposes a range of
routes, including but not limited to injec-
tion directly into the heart (often via a
custom delivery device), intramuscular in-
jection, and topical application. The wide-
ranging clinical indications and routes of
administration were also observed in
MSC clinical trials registered worldwide.
The varying understanding of how MSCs
may exert beneficial effects, and the often
unknown influence of clinical condition
and route of administration on an MSC-
based product’s bioactivity, leaves many
unanswered questions for the scientific
community to address.
We conducted an analysis of proof-of-
concept animal studies submitted to the
FDA that describe MSC-based product
characterization in vivo (48 MSC-based
product INDs submitted from 2007–
2011, a subset of the 66 submissions
assessed here). The majority of MSC-
based products are evaluated in proof-
of-concept animal studies. Many of the
study designs incorporated a combined
evaluation of the cellular product’s (1)
phenotype, (2) proliferative ability, (3) dis-
tribution, and (4) survival/persistence
postadministration, which may be useful144 Cell Stem Cell 14, February 6, 2014 ª201for determining a product’s MOA. While
no MSC-based product was evaluated
for all four of these parameters, 23% of
MSC-based products were evaluated for
three, 37% of products were evaluated
for two, and 14% of products were
evaluated for one of these parameters.
About one-fourth of submissions did not
report an evaluation of any of these
parameters in their proof-of-concept
animal studies. Specifically, when MSC-
based products were evaluated in animal
studies, proliferation and phenotype
postadministration were described for
less than 20% of the products, distribu-
tion was described for nearly two-thirds
of the products, and persistence was
always described for the products. The
contribution of assessing each of these
four parameters to better understand
what an MSC population contains and
how the cells exert biological activity is
yet to be determined.
Concluding Comments
Many stakeholders portray MSCs as well
understood, homogeneous cell types
with predictable properties. However,
there is significant diversity in how spon-
sors have defined, manufactured, and
described MSCs in regulatory submis-
sions to the FDA. This diversity is
apparent for tissue sourcing, product
manufacturing, cell surface marker
expression, and other in vitro and in vivo
MSC-based product characteristics re-
ported by sponsors. However, a subset
of seven cell surfacemarkers are routinely
identified in MSC-based product IND
submissions (CD105, CD73, CD90,
CD45, CD34, CD14, and HLA class II),
which is consistent with those markers
most commonly described in the litera-
ture. It remains unclear which particular
set of markers will be sufficient to
describe this complex and heteroge-
neous product class. In their 2006 posi-
tion paper, ISCT emphasized that their
proposed identifying criteria were not to
be confused with final product lot release
specifications developed for clinical trials
(Dominici et al., 2006). Interestingly, litera-
ture and regulatory submission descrip-
tions appear to indicate that many re-
searchers believe otherwise. In addition,
the fraction of ‘‘stem-like’’ cells in a popu-
lation of MSCs appears to be relatively
rare, quite heterogeneous, and can vary
in proportion depending on donor and tis-4 Elsevier Inc.sue source (i.e., interpopulation heteroge-
neity). Variation can be found even when
the same donor and tissue source is
utilized (i.e., in cases of intrapopulation
heterogeneity), which can further vary
based on manufacturing conditions. The
assumption that the most commonly
described marker set is sufficient to char-
acterize MSCs in order to understand
what an MSC population contains and
what its potential functions are may
pose a challenge for clinical translation
(and ultimately licensure) to be addressed
by the scientific community.
Further characterization of MSC-based
products to better understand the exis-
tence, phenotype, and impact of MSC
subpopulations may also be important
for advancing MSC-based therapies.
This is especially true for non-bone-
marrow-derived MSC-based products,
where even less information is often
described by sponsors. Early develop-
ment of assays and screening for MSC-
specific markers, an approach taken by
the FDA MSC Consortium (Lo Surdo
et al., 2013; Mindaye et al., 2013), contrib-
utes to our understanding of the composi-
tion of MSC-based products and their
in vitro and in vivo bioactivity. Markers
that can predict potential therapeutic
benefit may inform correlation of more
MSC characterization data with clinical
data as it becomes available. The ana-
lyses described herein are not meant to
imply that there is a defined set of charac-
terization markers that are required for
FDA approval. Rather, our goal is to high-
light potential challenges to the clinical
translation of MSC-based products in an
effort to inform research efforts support-
ing development of MSC-based cellular
therapies.
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